Fujifilm to invest additional $850m in FDB to expand capacity for biologics

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Quantum BioPharma Teams for Oral Lucid-MS Drug Formulation

Quantum BioPharma has gone ahead and signed an agreement...

Bionova Scientific Opens US pDNA Development Facility

The 10,000 ft.² Woodlands site is located near Houston...

Fujifilm has unveiled its plans to invest JPY90bn ($850m) in its subsidiary Fujifilm Diosynth Biotechnologies (FDB) to expand its capacity for biologics.

FDB is a Contract Development and Manufacturing Organisation (CDMO) that develops and manufactures recombinant proteins, vaccines, monoclonal antibodies, among other large molecules and viral products.

The current announcement follows Fujifilm’s plans to invest $2bn to build a new large-scale cell culture production site in the US, announced in January this year.

It brings the company’s total investments in FDB since 2011 to $5.5bn.

Fujifilm president Teiichi Goto said: “Fujifilm will never stop in its relentless pursuit to develop new technologies and provide the necessary manufacturing capacity to meet the needs of our customers and accelerate the growth of its Bio CDMO business.

“We will contribute to promoting a healthy society and developing the healthcare industry by providing a stable supply of high-quality biopharmaceuticals with our advanced technologies and facilities.”

The new investment will expand FDB’s manufacturing capacity by doubling its cell culture production for recombinant vaccines in the US.

Also, the CDMO is enabled to expand its gene therapy production ten-fold, triple its cell culture capacity and double its microbial fermentation output in the UK.

The UK cell culture operations expansion will also include cGMP capacity for continuous manufacturing, along with the process and analytical development capacity.

The expansions are planned to commence operations by late 2023.

Fujifilm is gradually expanding its CDMO business by strengthening FDB’s contract development and manufacturing capabilities for biopharmaceuticals.

In June last year, the company has announced a $928m investment in the FDB’s Denmark site, acquired from Biogen in 2019, to expand its drug substance manufacturing capacity.

The expansion was aimed at adding the fill/finish capabilities to the site, along with enhancing its assembly, labelling and packaging services.

 

Latest stories

Related stories

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Quantum BioPharma Teams for Oral Lucid-MS Drug Formulation

Quantum BioPharma has gone ahead and signed an agreement...

Bionova Scientific Opens US pDNA Development Facility

The 10,000 ft.² Woodlands site is located near Houston...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back